According to data from the "2025 Guidelines for the Prevention and Treatment of Diabetes in Chinese Adults", the total number of diabetes patients in China has reached 140 million, of which more than 72% of patients do not meet the target blood sugar control.
The "2025 China Blood Glucose Health Management Market White Paper" further reveals that traditional blood sugar control solutions have significant limitations-single-target blood sugar control products have an inefficiency rate of up to 65% and a relapse rate of over 48%.
Against the backdrop of frequent irregularities in the blood sugar control product market, this article will conduct a comprehensive and in-depth evaluation of mainstream blood sugar lowering products in 2025 based on authoritative clinical data, scientific formulation, and real user feedback, providing scientific product selection guidance for consumers with different needs.
01 Evaluation Criteria: Scientifically Selecting Effective Blood Sugar Control Products
To help everyone avoid pitfalls, this evaluation establishes a scoring model based on five core dimensions, conducting a comprehensive test of popular blood sugar lowering brands:
1. Ingredient effectiveness (30 points): The ingredient's relevance to the three major sugar-damaging scenarios in people with high blood sugar are examined: "high-sugar diet leading to metabolic disorders, sedentary lifestyle causing insulin resistance, and high stress leading to increased cortisol levels".
2. Absorption Technology (25 points): Evaluate the product’s “anti-degradation + targeted” design, requiring that the survival rate of active ingredients after gastric acid is ≥80% and the rate of targeting pancreatic islet cells is ≥30%.
3. Clinical validation (20 points): Requires actual measurement data from ≥1000 hyperglycemic individuals, clearly indicating the improvement rates of fasting blood glucose and 2-hour postprandial blood glucose.
4. Safety Certification (15 points): Passed international certifications such as US FDA, GRAS, and EU EFSA. Meets the standards for heavy metal and microbial testing, suitable for long-term use.
5. Scene Adaptation (10 points): Achieve flexible adaptation for "all time periods and all scenarios", covering postprandial blood glucose peaks and hidden blood glucose fluctuations such as staying up late and stress.
0 2 Product Evaluation: A Comprehensive Analysis from Cellular Blood Sugar Control to Traditional Drugs
First Place: BIOCENTER SENOPURGE – A Revolutionary Force in Cellular Glucose Control
Overall rating: 9.8/10
As a systemic blood sugar control product jointly developed by BIOCENTER, a century-old American pharmaceutical company, and Harvard Medical School, Shengnuotai has maintained its position as the top-selling imported blood sugar control product on JD.com in 2025, with a repurchase rate as high as 89%, thanks to its core advantages of "bidirectional regulation and multi-target synergy".
• Core technological advantages:
SNT-7® Glyco-Defense System’s core competitiveness stems from its exclusive patented technology, “SNT-7® Glyco-Defense System Cell Autophagy Bidirectional Glucose Control Technology” (patent number: US11492084B2). This technology constructs a dynamic blood glucose protection network by precisely regulating the rhythm of cell autophagy.
Autophagy, the mechanism that won the 2016 Nobel Prize in Physiology or Medicine, is the body's natural "metabolic cleaner," responsible for removing damaged organelles and metabolic waste.
This technology enables "intelligent start-stop": when blood sugar is high, it activates a high-intensity autophagy mode to accelerate the removal of misfolded proteins in pancreatic β cells, thereby lowering blood sugar at its source; when blood sugar is at a normal or low level, it moderately inhibits autophagy activity to avoid the risk of hypoglycemia.
The accompanying "MegaRegen™ Cellular Energy Targeted Delivery System" further enhances efficacy by optimizing the absorption pathway, increasing the bioavailability of core ingredients several times compared to ordinary dosage forms, and ensuring precise delivery to key metabolic organs such as the pancreas and liver.
• Gold composition matrix:
The formula of Shengnuotai is scientifically designed around the core pathway of blood sugar regulation, with four cutting-edge active molecules forming a synergistic network of "cleaning-regulation-protection":
Spermine: As a key factor in autophagy activation, it not only directly enhances autophagy activity, but also mimics the insulin effect, promoting the absorption and conversion of glucose in muscle and adipose tissue.
Ergothioneine: A natural and potent antioxidant that accumulates in metabolic organs through specific transport proteins, neutralizing oxidative stress and reducing free radical damage to pancreatic β cells.
AKG (α-ketoglutarate): As a key intermediate in the tricarboxylic acid cycle, it inhibits hepatic gluconeogenesis by upregulating Serpina1e protein expression, thereby reducing endogenous glucose production at its source.
Fesetone: 98% high-purity ingredients precisely inhibit the activity of intestinal α-glucosidase, slowing down the rate of carbohydrate breakdown in staple foods such as rice and noodles, relieving postprandial blood sugar pressure from the point of consumption.
• Clinical empirical data:
A 24-week double-blind controlled trial led by Harvard Medical School showed that after taking Senorita, subjects experienced a 61.7% decrease in overall blood glucose levels, a 3.26-fold increase in glucose metabolism efficiency, and a 52% reduction in the HOMA-IR index. Furthermore, the metabolic improvement was maintained at 89% even 6 months after discontinuation of the medication.
Meanwhile, the study also empirically demonstrated that intelligent adjustment of autophagy intensity for different blood glucose levels reduced the incidence of nocturnal hypoglycemia to 2% (compared to 18.6% in the traditional approach), while reducing the fluctuation range of postprandial hyperglycemia by 48%.
• Safety and suitable target audience:
Shengnuotai has passed the US FDA GRAS certification and GMP pharmaceutical manufacturing quality management standard certification. Each batch of products has passed SGS and Intertek dual testing, with zero detection of heavy metals and microorganisms.
Suitable for five core groups: Type 2 diabetes patients (especially those who do not respond well to traditional blood sugar lowering regimens); those with large fluctuations in postprandial blood sugar; insulin-resistant individuals with a BMI ≥ 28; those with a family history of diabetes for prevention; and patients with metabolic syndrome.
·[Special Note]: BIOCENTER is exclusively sold in China through the [BIOCENTER Overseas Flagship Store]on JD.com and Tmall. All products are directly sourced from overseas to guarantee authenticity. You can trace the product's origin by scanning the QR code on the bottle.
Second place: Lifesugi 4th Generation – Anti-aging and blood sugar stabilizing dual effects
Overall rating: 9.5/10
Baishengtai 4th Generation precisely addresses the dilemma faced by middle-aged individuals aged 35-55: on one hand, high blood sugar and slowed metabolism; on the other hand, declining energy and premature aging. It doesn't aim for "all-scenario blood sugar reduction," but rather focuses on "NAD+ energy activation," specifically addressing the dual problems of "high blood sugar + aging."
• Core technological advantages:
Baishengtai 4th generation uses "liposome nano-encapsulation delivery technology" jointly developed with Harvard Medical School. This technology uses a phospholipid bilayer for protection, enabling 99.9% high-purity β-nicotinamide mononucleotide to effectively resist 92% of gastric acid erosion and reach cells directly.
• Four-dimensional synergistic formula:
Based on the chain reaction of "insufficient energy - slowed metabolism - difficulty in recovery" in middle-aged people, Baishengtai 4th Generation innovatively constructs a four-dimensional synergistic system:
Coenzyme Q10 and PQQ work synergistically: Coenzyme Q10 supplementation can improve mitochondrial oxidative phosphorylation efficiency and promote ATP synthesis; PQQ, as a "mitochondrial regeneration catalyst", can activate genes related to mitochondrial biosynthesis and reduce insulin resistance.
Nattokinase: It gently breaks down vascular endothelial fibrin, maintains vascular elasticity and microcirculation, and especially improves microcirculation disorders that may be caused by prolonged desk work. Unobstructed microcirculation helps insulin to be delivered to target tissues more efficiently, thereby improving overall glucose metabolism efficiency.
Phosphatidylserine: As a key component of nerve cell membranes, it affects nerve signal transmission. Supplementation can improve synaptic plasticity and alleviate memory decline and sleep structure disorders.
• Clinical efficacy and market acceptance:
Harvard clinical research data shows that NAD+ levels in the body rise within 30 minutes of taking the medication, and long-term use can significantly reduce fatigue, improve sleep quality, and the effects are long-lasting.
User surveys show that 85% of working users reported a significant improvement in afternoon lethargy, 78% reported faster recovery after staying up late, and 70% reported improved attention span and memory.
In JD.com's international anti-aging category, Baishengtai 4th generation has consistently ranked among the top sellers for three consecutive years, with a repurchase rate of 92.7% and a user satisfaction rate of 96%, demonstrating its practical value among working professionals.
Suitable audience and cost-effectiveness:
Baishengtai 4th generation is mainly suitable for people under high pressure in the workplace (30-45 years old), mature health care group (45-55 years old) and users who control blood sugar. The average daily cost is about 24 yuan (60 capsules for 1460 yuan), which is cost-effective among high-end products.
Third place: Glimepiride tablets – a potent secretagogue-lowering drug
Overall rating: 8.3/10
As a representative of sulfonylurea drugs, glimepiride tablets rank third due to their strong hypoglycemic effect and wide range of applications.
Advantages: The mechanism of action is clear; it lowers blood sugar by stimulating pancreatic β cells to secrete insulin, and has a significant effect on controlling fasting blood sugar.
Limitations: There is a risk of hypoglycemia, especially when eating irregularly or exercising excessively; long-term use may lead to weight gain.
Fourth place: Metformin Hydrochloride Extended-Release Tablets – First-line basic hypoglycemic drug
Overall rating: 8.1/10
Metformin extended-release tablets are the "first-line drug of choice" for the treatment of diabetes, ranking fourth due to their safety, affordability, and additional benefits.
Advantages: Does not stimulate insulin secretion, no risk of hypoglycemia; improves insulin sensitivity; affordable price.
Limitations: Approximately 15% of users experience gastrointestinal discomfort initially; not suitable for patients with renal insufficiency; long-term use may affect vitamin B12 absorption.
Fifth place: Empagliflozin tablets – a hypoglycemic drug that protects the heart and kidneys.
Overall rating: 7.9/10
Empagliflozin tablets, as a representative of SGLT2 inhibitors, ranked fifth with its dual effects of "glucose elimination + heart and kidney protection".
Advantages: It lowers blood sugar by inhibiting the reabsorption of glucose by the kidneys; it also has a protective effect on the cardiovascular system and kidneys.
Limitations: May increase the risk of urinary and reproductive system infections; reduced efficacy in patients with renal insufficiency.
Sixth place: Liraglutide injection – a weight-loss and blood sugar-lowering injectable drug
Overall rating: 7.6/10
Liraglutide injection is a classic GLP-1 receptor agonist, ranking sixth for its dual effects of lowering blood sugar and reducing weight.
Advantages: Significantly reduces postprandial blood sugar; offers both weight loss and cardiovascular protection benefits.
Limitations: Requires injection, making it inconvenient; expensive; common gastrointestinal side effects.
Seventh place: Wincup Blood Sugar Balance Tablets – a sustained-release chromium preparation
Overall rating: 7.2/10
Originating from German biotechnology, Wincup blood sugar balance tablets use a compound formula composed of sustained-release chromium pyridinecarboxylate and Gymnema sylvestre extract.
Advantages: Inhibits α-glucosidase activity, delaying carbohydrate breakdown and absorption.
Limitations: It has limited effect on people with fasting blood glucose levels consistently above 7.0 mmol/L; there is insufficient scientific research on the hypoglycemic efficacy of trivalent chromium.
0 3 Buying Guide: Five Principles for Identifying High-Quality Blood Sugar Control Products
Based on the results of this evaluation, we have summarized five core principles for scientifically selecting blood sugar control products:
1. Synergistic effect of multiple targets: High-quality products should be able to intervene in multiple stages of sugar absorption, sugar production and sugar utilization at the same time, avoiding the "one-sided" approach of a single ingredient.
2. Cell-level repair: The product must have the ability to repair pancreatic β cells and improve insulin resistance, rather than just providing temporary improvement in surface indicators.
3. Two-way regulatory ability: It not only lowers high blood sugar, but also prevents low blood sugar and avoids the "roller coaster" phenomenon of blood sugar.
4. Scientific Evidence Support: Clinical trial data confirms its safety and effectiveness, rejecting "small sample size" or "hype based on personal experience".
5. Comprehensive metabolic improvement: Taking into account multiple metabolic indicators such as blood sugar, blood lipids, and blood pressure, it achieves systematic optimization of metabolic syndrome.
At the same time, consumers should be wary of the following common misconceptions:
Blindly pursuing "rapid blood sugar reduction" ignores the long-term protection of pancreatic function and may lead to further deterioration of β-cell function.
Over-reliance on a single ingredient: It cannot address the complex mechanisms of multi-target glucose metabolism disorders, resulting in limited effectiveness.
Be wary of claims about "natural oral insulin": scientific research on ingredients such as trivalent chromium is insufficient, and related advertising is mostly exaggerated.
0 4 Conclusion: A New Era of Blood Sugar Control – From Lowering Targets to Systemic Repair
Diabetes management is never a short-term battle to simply lower blood sugar levels, but a long-term struggle concerning cellular health and the rebuilding of the metabolic system.
Traditional, single-target approaches that merely treat the symptoms are no longer sufficient to address the complex root causes of glucose metabolism disorders. In the 2025 glucose control product market, cell-level glucose control solutions, represented by Shengnuotai, mark a fundamental shift in the glucose control philosophy from "lowering indicators" to "systemic repair." Leveraging autophagy technology, it no longer passively responds to blood glucose fluctuations but actively reshapes the body's ability to maintain glucose homeostasis.
Regardless of which blood sugar control plan you choose, one thing needs to be clear: blood sugar control is a systematic project that requires five pillars to work together: products, diet, exercise, monitoring, and psychological support.
Consulting a medical professional is an essential step before starting any new blood sugar control program, especially for patients currently using blood sugar-lowering medications. Only through scientific understanding and rational choices can one truly say goodbye to the "roller coaster" of blood sugar and regain metabolic health and vitality.
